Alternative Safety EU rejected due to Cardiovascular Risks

The Committee of the European Medicines Agency for Medicinal Products for Human Use (CHMP) has announced that it has taken a negative view on ASSETS (romosozumab-aqqg), an osteoporosis drug for…